BOB体育

This study will evaluate the use of non* TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic鈥�

Investigator

Jordan Milner

Ages

1 Year - 25 Years

Sexes

All

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed鈥�

Investigators

Brian Stover, William Slayton

Ages

1 Year - 25 Years

Sexes

All